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Purpose: Little is known about the toxicity of additional pelvic lymph node irradiation 
in men receiving intensity-modulated radiotherapy (IMRT) for prostate cancer. The aim of 
this study was to compare patient-reported outcomes following IMRT to the prostate only 
(PO-IMRT) versus the prostate and pelvic lymph nodes (PPLN-IMRT). 
Methods and Materials: Patients diagnosed with high-risk or locally advanced 
prostate cancer in the English National Health Service between April 2014 and September 
2016 treated with IMRT were mailed a questionnaire at least 18 months after diagnosis. 
Patient-reported urinary, sexual, bowel and hormonal functional domains on a scale from 0 




life were collected using the EPIC-26 and EQ-5D-5L. We used linear regression to compare 
PPLN-IMRT versus PO-IMRT with adjustment for patient, tumour and treatment 
characteristics. 
Results: Of the 7017 men who received a questionnaire, 5468 (77.9%) responded 
with 4196 (76.7%) having received PO-IMRT and 1272 (23.3%) PPLN-IMRT. Adjusted 
differences in EPIC-26 domain scores were smaller than 1 (p always >0.2) except for sexual 
function with men who had PPNL-IMRT reporting a lower mean score (adjusted difference 
2.3, 95% confidence interval 0.9 to 3.7; p=0.002), which did not represent a clinically 
relevant difference. There was no significant difference in HRQoL (p=0.5). 
Conclusions: Additional pelvic lymph node irradiation does not lead to clinically 
meaningful increases in the toxicity of IMRT for prostate cancer according to patient-




In the UK, the National Institute for Health and Care Excellence currently 
recommends considering pelvic lymph node (PLN) irradiation for patients with a high risk of 
nodal involvement (Roach score ≥15%) (1). However, according to results of the National 
Prostate Cancer Audit (NPCA), only 18% of men undergoing radiotherapy between 2010 and 
2013 with high-risk or locally advanced prostate cancer had PLN irradiation (2). 
Recently published results from the STAMPEDE trial support the routine use of 
radiotherapy in men with non-metastatic prostate cancer who have positive PLNs, where 
conformal or intensity-modulated radiotherapy was used (3). The 10-year follow-up results 




survival when used alongside androgen deprivation therapy (ADT) (4, 5), but results of other 
randomised controlled trials were inconclusive (6, 7). The relevance of all these trials is 
somewhat limited, given that they were conducted in the pre-dose-escalation era when 
radiotherapy doses did not exceed 64 Gy and intensity-modulated radiotherapy (IMRT) was 
not used. 
The use of PLN irradiation in clinical practice is limited, most likely because of 
concerns about its worse toxicity compared to prostate-only (PO) radiotherapy. However, 
we recently demonstrated that there is no evidence of an association between additional 
PLN irradiation and severe gastrointestinal (GI) and genitourinary (GU) toxicity within three 
years of IMRT. Our study included 3845 men diagnosed with prostate cancer between 2010 
and 2013 in England and used clinical measures of toxicity derived from linked national 
cancer registry, radiotherapy and administrative hospital data (8, 9). 
To date, studies have not used patient-reported outcome measures (PROMs) to 
compare patient groups who received IMRT with and without PLN irradiation. Studies using 
PROMs are needed because clinical measures based on clinical diagnostic and procedure 
data do not always fully capture the outcomes that are relevant to patients (10). We used 
data collated for the National Prostate Cancer Audit to compare patient-reported functional 
outcomes in patients, with high-risk or locally advanced prostate cancer, who had IMRT to 






MATERIAL AND METHODS 
Patient population 
This study used NPCA data derived from English Cancer Registry data (11), the 
National Radiotherapy Dataset (RTDS) (12) and Hospital Episode Statistics (HES) (13) to 
identify men who were diagnosed with prostate cancer between 1st April 2014 and 30th 
September 2016 and treated with radical radiotherapy. The International Classification of 
Diseases 10th Edition code ‘C61’ and cancer stage information from the cancer registry data 
was used to identify men with prostate cancer and the Office of Population Censuses and 
Surveys Classification of Interventions and Procedures Version 4 code ‘X671’in the RTDS was 
used to identify men who had received IMRT (14). 22,866 men with non-metastatic prostate 
cancer who received IMRT could be identified in this way (Figure 1). 
Prostate cancer risk was based on TNM stage, Gleason score, and PSA level 
according to a modified D’Amico risk stratification algorithm developed previously by the 
NPCA (8, 15). Men were excluded if they had intermediate-risk disease (n = 7353), low-risk 
disease (n = 254) or if prostate cancer risk was unknown (n = 458). 
The RTDS provided information on radiotherapy doses and number of attendances 
to classify each radiotherapy regimen. Men were excluded if they underwent a 
hypofractionated radiotherapy regimen (n = 4430), if they did not have a recognised 
radiotherapy regimen (n = 733), or if the radiotherapy treatment region could not be 
established (n = 53). Finally, men were excluded if they had moved or died (n = 71), or had 
received radiotherapy less than six months before completing the survey (n = 28). As a 





Patient questionnaires were mailed out to men eligible for inclusion at least 18 
months after diagnosis. Two reminders were sent out to non-responders 4 and 8 weeks 
after the initial mailing (Supplementary Material A). Median time from diagnosis to 
radiotherapy was 5.4 months (interquartile range [IQR]: 4.5 to 6.9) and 5.7 months (IQR: 4.7 
to 7.8), and median time from radiotherapy to survey completion was 16.2 months (IQR: 
13.8 to 22.1) and 15.1 months (IQR: 13.0 to 19.1) for the PO-IMRT and PPLN-IMRT groups, 
respectively. 
The questionnaire included the Expanded Prostate Cancer Index Composite 26-item 
version (EPIC-26), a validated instrument to measure functional outcomes in men with 
prostate cancer in the following five domains: urinary incontinence, urinary 
irritation/obstruction and sexual, bowel, and hormonal function (16). Each domain contains 
between 4-7 items. Scores were summarised for each domain on a scale of 0 to 100 with 
higher scores representing better function. The questionnaire also includes the EuroQol 
(EQ-5D-5L) which describes generic health-related quality of life (HRQoL) based on five 
domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with a 
score expressed on a scale with 0 representing ’death’ and 1 representing ’perfect health 
(17). Minimal clinically important differences (MCID), which are thresholds for clinically 
relevant differences, have been previously estimated for each EPIC-26 domain (urinary 
incontinence: 6 – 9 point change; urinary irritation/obstruction: 5 – 7 point change; sexual 
function: 10 – 12 point change; bowel function: 4 – 6 point change; and hormonal function: 






Primary outcomes were the five EPIC-26 domain scores and the EQ-5D-5L score 
according to treatment region (PO-IMRT versus PPLN-IMRT). Missing response data to 
individual questions were handled according to the specific guidelines for EPIC-26. An EPIC-
26 domain score was still calculated if at least 80% of the items that comprise a domain 
summary score were available (20). 
 
Explanatory variables 
The RTDS was used to determine the radiotherapy treatment region (PO and PPLN). 
Given that PPLN-IMRT is usually divided into a PPLN dose and a PO boost dose, it was only 
possible to ascertain the total PPLN dose and not the isolated dose delivered to the PLNs. 
HES records were used to determine age, ethnicity, socioeconomic deprivation according to 
the Index of Multiple Deprivation (21), and the number of comorbid conditions according to 
the RCS Charlson Score (22). T-stage, N-stage, M-stage, Gleason score and PSA were 
identified from the cancer registry data. Information on ADT use and number of comorbid 
conditions was available from the patient survey. Comorbidity data from the patient surveys 
was used for the primary analysis and the RCS Charlson score from HES was only used for 
the comparison between survey responders and non-responders.  
We identified GI and GU procedure codes in HES records of hospital admissions 
within one year before the start of radiotherapy as a proxy for baseline GI and GU function. 
The procedure codes were based on a previously developed coding framework, developed 
using administrative hospital records, to identify GI and GU toxicity of radiotherapy for 




patient survey, but we adjusted for GI and GU procedures recorded within one year before 
radiotherapy instead. 
The questionnaire in the second year of the study included three questions asking 
patients to recall urinary, bowel and sexual function at the time of diagnosis on a five-point 
scale ranging from “no problem” to “large problem” so that an assessment of function at 
the time of diagnosis could be made. 59%, 59% and 57% of the included men had available 
recall results for baseline urinary, bowel and sexual function. 
 
Statistical analysis 
Multivariable linear regression was used to compare outcomes (EPIC-26 domain and 
EQ-5D-5L scores) between the PO-IMRT and PPLN-IMRT groups. The comparison was 
adjusted for patient characteristics (treatment year, age, ethnicity, socioeconomic 
deprivation status [national quintiles], number of comorbidities [0, 1 or ≥2], pre-treatment 
GI and GU procedures, ADT use, and time between RT and completion of survey (6-12, 12-
18 and >18 months). A random intercept was modelled for each hospital to represent 
clustering of outcomes within hospitals. Missing values for adjustment variables (ethnicity) 
and outcomes were imputed using multiple imputation by chained equations so that we 
could include all survey responders. 25 data sets were created and Rubin’s rules were used 








Of the 7017 men eligible for inclusion in the study, 5468 (77.6%) responded. 
Responders tended to be older, more frequently of a white ethnic background, from less 
socially deprived areas and have fewer comorbidities, than non-responders. There were no 




Of the 5468 responders, 1272 (23.3%) received PLN irradiation (Table 1). There were 
only small differences in patient characteristics between the PO-IMRT and PPLN-IMRT 
groups. The median dose per fraction and total dose to the prostate were the same in both 
groups (2 Gy per fraction and 74 Gy, respectively). Men receiving PPLN-IMRT were more 
likely to have received ADT (83.4%) than men receiving PO-IMRT (78.6%). There were only 
little differences between the PO-IMRT and PPLN-IMRT groups in the frequency of men who 
had received GU procedures (21.0% and 22.5%, respectively) or GI procedures (5.4 and 
4.8%, respectively) within one year before the start of radiotherapy. 
There were no relevant differences between the PO-IMRT and the PPLN-IMRT 
groups in their recall of bowel and sexual function at the time of diagnosis. Of those who 
had PO-IMRT, 2.0% and 21.2% rated their bowel and sexual function as a “large problem”, 
respectively, with corresponding percentages for those who had PPLN-IMRT being 1.8% and 
19.5%, respectively. However, more men who had PPLN-IMRT rated their urinary function at 






Mean EPIC-26 scores were between 85.5 and 86.8 for urinary and bowel function 
domains. Scores were lower for hormonal function (PPLN-IMRT: 65.3; PO-IMRT: 70.3) and 
very low for sexual function (PPLN-IMRT: 13.0; PO-IMRT: 14.1) (Table 2). 
The PPLN-IMRT group had a lower mean EPIC-26 sexual function score than the PO-
IMRT group but the difference was small (adjusted difference 2.3, 95% confidence interval 
0.9 to 3.7), and did not meet the recognised threshold for a clinically relevant difference 
(Table 2). Differences in the other EPIC-26 domain scores between the treatment groups 
(urinary incontinence, urinary irritation/obstruction, bowel function and hormonal function) 
were small (always < 1) and not statistically significant. EQ-5D-5L scores were not 
statistically different between groups either (both 0.84), where a clinically meaningful 




There were no clinically relevant differences in function or generic HRQoL between 
men who were treated with either PO-IMRT or PPLN-IMRT, according to outcomes they 
reported themselves at least 18 months after being diagnosed with high-risk or locally 
advanced prostate cancer. This is the first study to use PROMs to compare PO and PPLN 
irradiation using modern dose-escalation techniques showing that additional irradiation of 





Comparison with other studies 
Three relatively small studies have previously used PROMs to assess the toxicity of 
additional PLN irradiation. Two of these studies used 3D-conformal radiotherapy and did not 
find clinically relevant differences in HRQoL between 12 and 24 months after the end of 
radiotherapy. The first was a randomised controlled trial of 444 patients published in 2007, 
and the second was a cohort study of 120 patients published in 2011 (7, 24). The third study 
was a cohort study of 120 patients, and published in 2014, which used IMRT to treat the 
PLNs and 3D-conformal radiotherapy to treat the prostate (25). This study found that 
urinary and bowel function were worse for the PPLN group at three months after 
radiotherapy but function was comparable at 12 months, representing a difference in acute 
toxicity which resolved over time. 
Results from studies using clinician-reported outcome measures are in line with the 
studies using PROMs. One small cohort study of 277 patients, using IMRT to treat the 
prostate and a four-field technique for the PLNs, showed that there were no longer-term 
differences between those who did and did not have PLN irradiation (26). Similarly, a study 
that we carried out recently, using linked national datasets, to compare 3065 men who had 
PO-IMRT and 780 who had PPLN-IMRT found no evidence of differences in GI or GU toxicity 
3 years after diagnosis (2). 
 
Strengths and Limitations 
The strengths of the current study include the relatively large number of patients 
(n=5468), the high response rate to the survey (78%), and the use of validated instruments 
to collect PROMs at a specified time after diagnosis. It is the largest study to date comparing 




PPLN-IMRT. A further strength is that we used recent national datasets which ensures that 
our results are fully representative of modern-day clinical practice. 
The main limitation of the study was the lack of baseline PROMs (EPIC-26 and EQ-5D-
5L scores) at the time of diagnosis but the regression analyses were still adjusted for 
important patient characteristics and prior GI and GU procedures. Therefore the impact of 
including baseline PROMs in the models is likely to be small given that they will only be 
supplying additional adjustment over and above what is already captured. We also included 
three questions in the patient survey asking patients to recall their baseline urinary, bowel 
and sexual function. Our results show that more men who had PPLN-IMRT rated their 
urinary function at the time of diagnosis as a “large problem” compared to men who had 
PO-IMRT. If there was residual confounding present due to this difference in baseline 
urinary function we would expect the observed results to indicate worse urinary function 
after PPLN-IMRT compared to PO-IMRT. Given that this is not the case, residual confounding 
is likely to be small and further supports the interpretation of our findings that additional 
PLN irradiation does not increase long-term toxicity compared to PO-IMRT. In addition, for 
57% of the study cohort where recalled baseline function results were available, a sensitivity 
analysis was performed adjusting for these additional variables and results were the same 
as the overall study results. 
Although the response rate was high for a national patient survey, we need to 
consider the potential impact of selective non-response. It is important to note that the 
response rates did not vary between the PO-IMRT and PPLN-IMRT groups. Also, the 
differences we report are adjusted for patient characteristics which have been shown to be 
associated with survey response (age and comorbidity), which further reduces the impact of 





The life expectancy of men with prostate cancer is increasing and as a result men are 
living longer with their disease as well as with their treatment-related side effects (27, 28). 
PROMs are therefore providing essential information for the evaluation of the benefits and 
harms of radical prostate cancer treatment (29, 30). 
We did not find evidence that PPLN-IMRT is associated with clinically relevant 
differences in longer-term functional outcomes or HRQoL. This suggests that PPLN-IMRT 
should be considered in patients with high-risk or locally advanced prostate cancer, 
especially given emerging evidence that relapse patterns are often nodal-centric (31). In 
addition, with the advent of molecular imaging, men can be more appropriately assessed 
with respect to lymph node involvement. This will improve decision making with regards to 
the inclusion of pelvic lymph nodes within the radiation field as part of primary treatment or 
when used in the salvage setting. 
 
CONCLUSION 
There are no clinically relevant differences in functional outcomes or HRQoL in men 
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Figure 1. Flowchart of patient selection 
 
